Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025. ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing ...

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the ...

New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing therapy targeting lipoprotein((a)) [Lp((a))], a risk factor associated ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq ...